METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major cancer trial tests if adding one drug helps patients live longer
Disease control Recruiting nowThis large, late-stage trial is testing which of two chemotherapy combinations works better for people with advanced stomach or esophageal cancer that has spread and cannot be removed by surgery. About 382 participants will be randomly assigned to receive either the standard two-…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New hope for Tough-to-Treat cancers: adding immune booster to standard care
Disease control Recruiting nowThis study is for people with advanced stomach or esophageal cancer that has worsened after initial treatment. It tests if adding an immunotherapy drug called nivolumab to the standard two-drug chemotherapy helps control the cancer better and helps patients live longer. About 224…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Scientists test 'One-Two Punch' against Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of a new two-drug combination for people with advanced solid tumors that have a specific marker called HER2. The treatment pairs an existing targeted cancer drug with a new pill that aims to block cancer cells' ability to…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Radiation 'Jump-Starts' immune system to fight spreading cancers
Disease control Recruiting nowThis study is for people with advanced gastrointestinal cancers that have spread and have stopped responding to immunotherapy. Researchers want to see if giving a short, targeted course of radiation to one tumor can 'wake up' the body's immune system to attack all the cancer, inc…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Five-Pronged attack on tough stomach cancers
Disease control Recruiting nowThis study is testing a new combination of five different treatments for people with advanced stomach or esophageal cancer that has worsened after one prior therapy. The goal is to see if this multi-drug approach can better control the cancer. The treatment includes two immunothe…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Scientists test 'Double Punch' drug combo for Tough-to-Treat stomach cancers
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of a new two-drug combination for people with advanced cancers that have a specific marker called HER2. The trial focuses on stomach and gastroesophageal junction cancers that have spread or cannot be removed by surgery, …
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Stress-Blocking pill joins fight against tough stomach cancers
Disease control Recruiting nowThis study is testing if adding propranolol, a common blood pressure and anxiety medication, makes standard chemotherapy and immunotherapy more effective for people with advanced cancer where the esophagus meets the stomach. The idea is that stress hormones might weaken the immun…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New drug duo tested for Tough-to-Treat stomach cancers
Disease control Recruiting nowThis early-stage study is testing whether combining two existing drugs, pembrolizumab and lenvatinib, can help control advanced stomach or gastroesophageal cancers that have spread or cannot be surgically removed. The trial is for adults whose cancer has continued to grow despite…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New drug duo tested to fight advanced GI cancers
Disease control Recruiting nowThis early-stage study aims to find the safest and most effective dose of a new two-drug combination for people with advanced colorectal or gastroesophageal (stomach/esophagus) cancers that have spread. The trial will enroll about 45 adults whose cancer has progressed after at le…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
Custom-Made vaccine aims to train immune system to fight advanced cancers
Disease control Recruiting nowThis study is testing a new, personalized vaccine designed to target the unique proteins on a patient's own cancer cells. It is being given alongside an existing immunotherapy drug (pembrolizumab) to see if the combination is safe and can help control advanced solid tumors that h…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC